- United States
- United Kingdom
Consulte evidencias clínicas sobre los métodos quirúrgicos y pruebas de diagnóstico más avanzados para el tratamiento de patologías anorrectales.
Screening for Squamous Cell Anal Cancer in HIV Positive patients: a Five-Year Experience - Screening for Squamous Cell Anal Cancer in HIV Positive patients: a Five-Year Experience - THDLAB - ES
Screening for Squamous Cell Anal Cancer in HIV Positive patients: a Five-Year Experience
Cavazzoni E., Leo A.C., Cantarella F., Baldelli F., Santorelli C. et al Journal of Investigative Surgery, 0,1-7, 2017
- Recurso online https://www.ncbi.nlm.nih.gov/pubmed/28644711
Potential screening modalities for early diagnosis of squamous cell anal cancer (SCC) in HIV patients include digital anorectal examination (DARE), anal Papanicolaou testing (Pap test), human papilloma virus (HPV) co-testing, and high-resolution anoscopy. The aim of this study was to demonstrate the results of a five-year screening program for SCC in HIV patients.
MATERIALS AND METHODS:
We conducted a retrospective study on 204 HIV patients who underwent a screening program for SCC from October 2010 to January 2015. All patients were screened by DARE, anal Pap test, including HPV test and cytology, and high-resolution video-proctoscopy (HR-VPS) with and without acetic acid 3%. Depending on macroscopic appearance and biopsies, patients underwent observa-tion or treatment. Median follow-up was 36 months.
Cytologic abnormalities (Cyt+) for high-risk HPV genotypes were recorded in 34% of patients. HR-VPS was positive in 59 patients (29%), of whom 13 patients (22%) were positive for warts; the rest have typical features of anal intraepithelial neoplasia (AIN). Sixteen (8%) patients had AIN (AIN I–III) and underwent wide local excision, ablation, or imiquimod. Absence of progression was recorded. Fourteen patients (7%) had SCC: eight (57%) with no evidence of recurrence, two (14%) had recurrence, and four (29%) died from metastatic disease.
Our data demonstrated a successful screen-ing program in preventing SCC in HIV patients. We demonstrate the advantages of progression towards SCC. Moreover, we used a new screening tool, the HR-VPS, a low-cost and manageable instrument to collect patients’ long-term data.